1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Neoantigens Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Neoantigens Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1
- 5.1.2 Biotechnology developments increasing
- 5.1.3 Cancer driving personalized immunotherapies
- 5.1.4 Advances in genomic sequencing enhancing therapies
- 5.1.5
5.2 Market Opportunities
- 5.2.1
- 5.2.2 Expansion of collaborations between biotech firms and academic institutions for neoantigen discovery and validation.
- 5.2.3 Rising interest in neoantigen vaccines and therapeutic approaches as adjuncts to existing cancer treatments.
- 5.2.4 Potential for application in autoimmune diseases and other therapeutic areas leveraging neoantigen targeting.
5.3 Future Trends
- 5.3.1
- 5.3.2 Development of AI and machine learning tools for more efficient neoantigen prediction and identification.
- 5.3.3 Increasing use of combination therapies incorporating neoantigens with checkpoint inhibitors for enhanced efficacy.
- 5.3.4 Advancements in personalized vaccine platforms using neoantigens to boost immune responses in cancer patients.
5.4 Impact of Drivers and Restraints
6. North America Neoantigens Market Regional Analysis
6.1 North America Neoantigens Market Overview
6.2 North America Neoantigens Market Revenue 2021-2028 (US$ Thousand)
6.3 North America Neoantigens Market Forecast Analysis
7. North America Neoantigens Market Analysis – by Treatment
7.1 Combination Therapy and Mono Therapy
- 7.1.1 Overview
- 7.1.2 Combination Therapy and Mono Therapy: North America Neoantigens Market – Revenue and Forecast to 2031 (US$ Thousand)
8. North America Neoantigens Market Analysis – by Therapeutic Specialty
8.1 Gastrointestinal Cancer
- 8.1.1 Overview
- 8.1.2 Gastrointestinal Cancer: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
8.3 Solid Tumor
- 8.3.1 Overview
- 8.3.2 Solid Tumor: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
8.4 Urinary Systems Cancers
- 8.4.1 Overview
- 8.4.2 Urinary Systems Cancers: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
8.5 Melanoma
- 8.5.1 Overview
- 8.5.2 Melanoma: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
8.6 Head and Neck Cancer
- 8.6.1 Overview
- 8.6.2 Head and Neck Cancer: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
9. North America Neoantigens Market – North America Analysis
9.1 North America
- 9.1.1 North America Neoantigens Market Breakdown, by Key
Country, 2024 and 2028 (%)
- 9.1.1.1 North America Neoantigens Market – Revenue and
Forecast Analysis – by Country
- 9.1.1.1 US:
North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
- 9.1.1.1.1 US: North America Neoantigens Market Breakdown, by Treatment
- 9.1.1.1.2 US: North America Neoantigens Market Breakdown, by Therapeutic Specialty
- 9.1.1.2 Canada:
North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
- 9.1.1.2.1 Canada: North America Neoantigens Market Breakdown, by Treatment
- 9.1.1.2.2 Canada: North America Neoantigens Market Breakdown, by Therapeutic Specialty
- 9.1.1.3 Mexico :
North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
- 9.1.1.3.1 Mexico : North America Neoantigens Market Breakdown, by Treatment
- 9.1.1.3.2 Mexico : North America Neoantigens Market Breakdown, by Therapeutic Specialty
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. North America Neoantigens Market Industry Landscape
11.1 Overview
11.2 Mergers and Acquisitions
11.3 Agreements, Collaborations, and Joint Ventures
11.4 New Product Launches
11.5 Expansions and Other Strategic Developments
12. Company Profiles
12.1 Advaxis, Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Gradalis, Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Gritstone Oncology
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Medigene AG
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Moderna, Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Ziopharm Oncology, Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
13. Appendix
13.1 About Business Market Insights
Get Free Sample For North America Neoantigens Market
